Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2007-05-29
2007-05-29
Wehbé, Anne Marie (Department: 1633)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C424S278100, C424S283100, C424S490000, C435S320100, C435S455000
Reexamination Certificate
active
09433777
ABSTRACT:
Reagents useful in nucleic acid immunization techniques are described. More particularly, adjuvanted genetic vaccine compositions are described, as are methods of using those compositions for inducing an enhanced immune response against a selected antigen.
REFERENCES:
patent: 4945050 (1990-07-01), Sanford et al.
patent: 5015580 (1991-05-01), Christou et al.
patent: 5036006 (1991-07-01), Sanford et al.
patent: 5100792 (1992-03-01), Sanford et al.
patent: 5112749 (1992-05-01), Brey, III et al.
patent: 5120657 (1992-06-01), McCabe et al.
patent: 5149655 (1992-09-01), McCabe et al.
patent: 5204253 (1993-04-01), Sanford et al.
patent: 5584807 (1996-12-01), McCabe
patent: 5589466 (1996-12-01), Felgner et al.
patent: 5630796 (1997-05-01), Bellhouse et al.
patent: 5738852 (1998-04-01), Robinson et al.
patent: 5865796 (1999-02-01), McCabe
patent: 5925362 (1999-07-01), Spitler et al.
patent: 6168587 (2001-01-01), Bellhouse et al.
patent: 6194389 (2001-02-01), Johnston et al.
patent: WO 91/00359 (1991-01-01), None
patent: WO 91/07487 (1991-05-01), None
patent: WO 93/17706 (1993-09-01), None
patent: WO 94/24263 (1994-10-01), None
patent: WO 95/19799 (1995-07-01), None
patent: WO 96/04947 (1996-02-01), None
patent: WO 96/12513 (1996-05-01), None
patent: WO 96/14855 (1996-05-01), None
patent: WO 96/20022 (1996-07-01), None
patent: WO 97/40163 (1997-01-01), None
patent: WO 97/32987 (1997-09-01), None
patent: WO 97/48485 (1997-12-01), None
patent: WO 98/10750 (1998-03-01), None
patent: WO 98/46263 (1998-10-01), None
patent: WO 99/27961 (1999-06-01), None
patent: WO 00/12121 (2000-03-01), None
patent: WO 00/13704 (2000-03-01), None
Sedegah et.al.; Protection aganist malaria by immunization with plasmid DNA encoding circumsporozoite protein, 1994, Proc. Natl. Acad., vol. 91: 9866-9870.
Abbas et.al.; Functional diversity of helper T Lymphocytes, 1996, Nature, vol. 383: 787-783.
Golding et.al.; The Potential for Recruiting Immune Responses Toward Type 1 or Type 2 T Cell Help, 1994, American Society if Tripical Medicine and Hygiene: 33-40.
Haynes J R, “Generic Vaccines,”Infectious Disease Clinincs Of North America. 13(1):11-26 (1999).
Sasaki et al., “The Search for a Potent DNA Vaccine against AIDS: The Enhancement of Immunogenicity by Chemical & Genetic Adjuvants”,Anticancer research18:3907-3916 (1998).
Sasaki et al., “Monophosphoryl Lipid A Enchances Both Humoral & Cell-Mediated Immune Responses to DNA Vaccination against Human Immunodeficiency Virus Type 1”,Infection & immunity. 65(9):3520-3528 (1997).
Lodmell et al., “DNA Vaccination of mice against rabies virus: effects of the route of vaccination and adjuvent monophosphoryl lipid A (MPL)”Vaccine. 18:1059-1066 (2000).
Pow & Crook, “Extremely high titre polyclonal antisera against small neurotransmitter molecules: rapid production, Charcterisation and use in light-and electron-microscopic immunocytochemistry”,J. of Neuroscience Methods. 48:51-63 (1993).
Larsen et al., “Coadministration of DNA Encoding Interleukin-6 and Hemagglutinin Confers Protection from Influenza Virus Challenge in Mice”, Journal of Virology, Feb. 1997, pp. 1704-1708, vol. 72, No. 2.
ICN Biochemicals, Inc., “Biochemicals, Organic Chemicals, Radiochemicals, Cell Biology, Immuno Biologicals, Diagnostics”, Index, ICN Biochemicals, Inc. 3300 Hyland Avenue, Costa Mesa, CA (1991-1992).
Johnston et al., “Biolistic Transformation of Animal Tissue”, In Vitro Cell. Dev. Biol. 27, Jan. 1991, pp. 11-14.
Klein et al., “High-Velocity Microprojectiles for Delivering Nucleic Acids into Living Cells”, Nature, pp. 70-73, vol. 327, May 7, 1987.
Orkin et al., “Report and Recommendations of the Panel to Assess the NIH Investment in Research on Gene Therapy”, Dec. 7, 1995.
Sanford et al., “Delivery of Substrates into Cells and Tissues Using a Particle Bombardment Process”, Particulate Science and Technology 5, 1987, pp. 27-37, Hemisphere Publishing Corporation.
Clinical Research, Apr. 1994, vol. 42, No. 2.
Stryer, “Synthesis of a Specific Antibody Following Exposure to an Antigen”, 1975, p. 732, W.H. Freeman and Company, San Francisco, CA.
Tang et al., “Genetic Immunization is a Simple Method for Eliciting an Immune Response”, Nature, Mar. 12, 1992, pp. 152-154, vol. 356.
Ulmer et al., “Heterologous Protection Against Influenza by Injection of DNA Encoding a Viral Protein”, Science, Mar. 19, 1993, pp. 1745-1749, vol. 259.
Yang et al., “In Vivo and In Vitro Gene Transfer to Mammalian Somatic Cells by Particle Bombardment,” Proc. Natl. Acad. Sci. USA, Dec. 1990, pp. 9568-9572, vol. 87.
Xiang et al., “Manipulation of the Immune Response to a Plasmid-Encoded Viral Antigen by Coinoculation with Plasmids Expressing Cytokines”, Immunity, Feb. 1995, pp. 129-135, vol. 2, Cell Press.
Fuller Deborah
Fuller James T.
Haynes Joel R.
Shipley Timothy
Widera Georg
Powderject Vaccines, Inc.
Wehbe Anne Marie
LandOfFree
Adjuvanted genetic vaccines does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Adjuvanted genetic vaccines, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Adjuvanted genetic vaccines will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3825363